These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16794212)

  • 41. Does the National Institutes of Health Stroke Scale favor left hemisphere strokes? NINDS t-PA Stroke Study Group.
    Woo D; Broderick JP; Kothari RU; Lu M; Brott T; Lyden PD; Marler JR; Grotta JC
    Stroke; 1999 Nov; 30(11):2355-9. PubMed ID: 10548670
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Intravenous rt-PA for acute ischemic stroke: 69 consecutive patients managed in an emergency stroke centre].
    Tardy J; Albucher JF; Parienté J; Chollet F
    Rev Neurol (Paris); 2007 Mar; 163(3):349-57. PubMed ID: 17404522
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nonatrial Fibrillation was Associated With Early Neurological Improvement After Intravenous Thrombolysis With rt-PA in Patients With Acute Ischemic Stroke.
    Liu J; Huang J; Xu H; Dai H
    Neurologist; 2020 Mar; 25(2):28-32. PubMed ID: 32132497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does clinical-CT 'mismatch' predict early response to treatment with recombinant tissue plasminogen activator?
    Choi JY; Pary JK; Alexandrov AV; Molina CA; Garami Z; Malkoff MD; Rubiera M; Shaltoni HM; Moye LA; Grotta JC
    Cerebrovasc Dis; 2006; 22(5-6):384-8. PubMed ID: 16888380
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.
    Schwammenthal Y; Drescher MJ; Merzeliak O; Tsabari R; Bruk B; Feibel M; Hoffman C; Bakon M; Rotstein Z; Chapman J; Tanne D
    Isr Med Assoc J; 2004 Feb; 6(2):70-4. PubMed ID: 14986460
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of metabolic syndrome and obesity on outcomes of acute ischemic stroke patients treated with systemic thrombolysis.
    Bas DF; Ozdemir AO
    J Neurol Sci; 2017 Dec; 383():1-4. PubMed ID: 29246591
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial.
    Grotta JC; Welch KM; Fagan SC; Lu M; Frankel MR; Brott T; Levine SR; Lyden PD
    Stroke; 2001 Mar; 32(3):661-8. PubMed ID: 11239184
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute Ischemic Stroke with Very Early Clinical Improvement: A National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trials Exploratory Analysis.
    Balucani C; Levine SR; Khoury JC; Khatri P; Saver JL; Broderick JP
    J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):894-901. PubMed ID: 26825352
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS).
    Hacke W; Kaste M; Fieschi C; Toni D; Lesaffre E; von Kummer R; Boysen G; Bluhmki E; Höxter G; Mahagne MH
    JAMA; 1995 Oct; 274(13):1017-25. PubMed ID: 7563451
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI.
    Schellinger PD; Jansen O; Fiebach JB; Heiland S; Steiner T; Schwab S; Pohlers O; Ryssel H; Sartor K; Hacke W
    Stroke; 2000 Jun; 31(6):1318-28. PubMed ID: 10835451
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Large-Vessel Occlusion Stroke: Effect of Recanalization on Outcome Depends on the National Institutes of Health Stroke Scale Score.
    Skagen K; Skjelland M; Russell D; Jacobsen EA
    J Stroke Cerebrovasc Dis; 2015 Jul; 24(7):1532-9. PubMed ID: 25922156
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Retrospective Study of thrombolysis with 0.6 mg/kg Recombinant Tissue Plasminogen Activator (rt-PA) in Mild Stroke.
    Yang J; Yu F; Liu H; An H; Xiong R; Huang D
    Sci Rep; 2016 Aug; 6():31344. PubMed ID: 27510959
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characteristics and Outcomes of Patients who Refuse Intravenous Thrombolysis for Acute Ischemic Stroke - The San Diego Experience.
    von Kleist T; Meyer D; Rapp K; Meyer BC; Modir R
    J Stroke Cerebrovasc Dis; 2020 Nov; 29(11):105137. PubMed ID: 33066942
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China.
    Yan X; Hu HT; Liu S; Sun YH; Gao X
    Neurol Res; 2015 Apr; 37(4):352-8. PubMed ID: 25297471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Could clinical diffusion-mismatch determined using DWI ASPECTS predict neurological improvement after thrombolysis before 3 h after acute stroke?
    Terasawa Y; Kimura K; Iguchi Y; Kobayashi K; Aoki J; Shibazaki K; Kaji R
    J Neurol Neurosurg Psychiatry; 2010 Aug; 81(8):864-8. PubMed ID: 20562433
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Eligibility determination for intravenous thrombolysis based on radiology interpretation report of the head CT scan in patients with acute ischemic stroke.
    Hassan AE; Majidi S; Janjua NA; Chaudhry SA; Tekle WG; Grigoryan M; Qureshi AI
    J Neuroimaging; 2014; 24(4):349-53. PubMed ID: 24015702
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Utilization of intravenous thrombolysis in 3-4.5 hours: analysis of the Minnesota stroke registry.
    Tekle WG; Chaudhry SA; Hassan AE; Peacock JM; Lakshminarayan K; Tsai A; Luepker R; Anderson DC; Qureshi AI
    Cerebrovasc Dis; 2012; 34(5-6):400-5. PubMed ID: 23221276
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical deterioration after intravenous recombinant tissue plasminogen activator treatment: a multicenter transcranial Doppler study.
    Saqqur M; Molina CA; Salam A; Siddiqui M; Ribo M; Uchino K; Calleja S; Garami Z; Khan K; Akhtar N; O'Rourke F; Shuaib A; Demchuk AM; Alexandrov AV;
    Stroke; 2007 Jan; 38(1):69-74. PubMed ID: 17138949
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prospective, open-label safety study of intravenous recombinant tissue plasminogen activator in wake-up stroke.
    Barreto AD; Fanale CV; Alexandrov AV; Gaffney KC; Vahidy FS; Nguyen CB; Sarraj A; Rahbar M; Grotta JC; Savitz SI;
    Ann Neurol; 2016 Aug; 80(2):211-8. PubMed ID: 27273860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.